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Abstract
Genome-wide association studies have identified a coronary artery disease (CAD) risk locus in a non-coding region at
9p21.3, the nearest genes being CDKN2A and CDKN2B. To understand the pathways by which this locus might influence
CAD susceptibility, we investigated associations between the 9p21.3 risk genotype and global gene expression in heart
tissue from donors with no diagnosed heart disease (n=108, predominant cause of death, cerebral vascular accident) and in
carotid plaque (n=106), aorta (n=104) and mammary artery (n=88) tissues from heart valve and carotid endarterectomy
patients. Genotyping was performed with Taqman assays and Illumina arrays, and gene expression profiles generated with
Affymetrix microarrays. Associations were analyzed with an additive genetic model. In heart tissue, 46 genes were putatively
altered in association with the 9p21.3 risk allele (70% down-regulated, fold-change .1.1 per allele, p,0.05 adjusted for age,
gender, ethnicity, cause of death). These genes were enriched for biomarkers of myocardial infarction (p=1.53610
29),
response to wounding (p=2.65610
210) and inflammatory processes (p,1.97610
27). Among the top 10 most down-
regulated genes, 7 genes shared a set of transcription factor binding sites within conserved promoter regions
(p,1.14610
25), suggesting they may be co-regulated. Canonical pathway modelling of the most differentially expressed
transcripts across all tissues (154 genes, 60% down-regulated, fold-change .1.1 per allele, p,0.01) showed that 75% of the
genes could be transcriptionally regulated through the cell cycle G1 phase progression pathway (p,1.08610
2258), in which
CDKN2A and CDKN2B play a regulatory role. These data suggest that the cell cycle G1 phase progression pathway is
activated in individuals with the 9p21.3 risk allele. This may contribute to a proliferative phenotype that promotes adverse
cardiac hypertrophy and vascular remodeling, leading to an increased CAD risk.
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Introduction
Coronary artery disease (CAD) is a leading cause of mortality
and morbidity worldwide [1]. Susceptibility to CAD is influenced
by combined effects of environmental and inherited genetic
factors, and consequently some families are particularly affected
[2]. In 2007, several genome-wide association studies consistently
identified a region on chromosome 9p21.3 as being the most
strongly associated with CAD [3,4,5,6]. This finding has been
replicated in multiple case-control studies in several population
groups in numerous ethnicities [7,8,9,10,11,12,13,14,15], making
9p21.3 the most replicated molecular genetic association with
coronary heart disease to date. Other variants at chromosome
9p21.3 have been linked with susceptibility to several other
complex diseases including type 2 diabetes [16,17], aortic
aneurism [18], ischemic stroke [19,20], several cancers
[21,22,23,24,25,26,27,28,29] and frailty [30].
Within the 9p21.3 locus, multiple single nucleotide polymor-
phisms (SNPs) in strong linkage disequilibrium have been
associated with CAD [3,6,31]. The risk (minor) allele occurs with
high frequency among many populations (minor allele frequency
,50% in European populations) [8,10,11,12,13,14] and confers a
modest, yet highly reproducible increase in risk of approximately
1.3-fold per copy [31]. It has been suggested that the 9p21.3 locus
may have clinical utility as an early marker for CAD susceptibility
[32].
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appears to be independent of established risk factors, including
elevated lipid levels, high blood pressure, obesity and diabetes
[5,9,12], and the mechanism underlying the association remains
enigmatic. The risk locus contains no protein coding genes or
known microRNAs. The nearest genes, approximately 100 kb
upstream of the risk locus, are a pair of tumor suppressor genes
(cyclin dependent kinase inhibitors, CDKN2A and CDKN2B) that
are involved in regulation of the cell cycle and have no
demonstrated role in CAD to date. The risk locus overlaps exons
13–20 of a recently identified large, non-coding, antisense RNA of
unknown function, named ANRIL (antisense noncoding RNA in
the INK4 locus, also known as CDKN2BAS) [33]. ANRIL, like other
non-coding RNAs, is predicted to play a role in regulation of gene
expression and is expressed in cells and tissues that are affected by
atherosclerosis [9]. Variants associated with CAD are located
within intronic and 39 flanking sequences and recent data suggest
that these, and other variants in close proximity, mediate risk of
CAD by altering expression of ANRIL (and possibly decreasing
expression of CDKN2A and CDKN2B) via multiple, independent
cis-regulatory elements [34,35] and, more specifically, by influ-
encing the expression and structure of individual splice variants
produced from the ANRIL gene [36,37,38,39,40]. The region
contains a dense assembly of gene expression enhancers and two
CAD risk SNPs are located in one of these motifs, which disrupts a
binding site for the transcription factor, STAT1 [35]. Less clear
are the risk allele-associated changes in expression of CDKN2A and
CDKN2B; two reports find they are both concordantly decreased
with ANRIL [38,40], while decreased CDKN2A [34] and increased
CDKN2B expression has also been reported [34], as well as strong
evidence for direct involvement of ANRIL in epigenetic repression
of both CDKN2A and CDKN2B [41,42]. The downstream effects of
altered activation of these regulators of the cell cycle progression
pathway on CAD risk remain unknown.
We now have a greater understanding of the regulatory events
at the genomic region proximal to the risk locus, but to understand
the mechanism underlying the association between 9p21.3 and
CAD, pathways involved in disease susceptibility in tissues critical
to its pathogenesis need to be defined. Further downstream targets
of ANRIL linking this genomic region to atherosclerotic processes
fundamental to CAD have yet to be determined. We hypothesized
that variants within the 9p21.3 risk locus may be associated with
altered expression of genes in myocardial and vascular tissues,
which contributes to the development of cardiovascular pathology.
To test this hypothesis and identify pathways that might be
influenced by the 9p21.3 variants, we investigated associations
between rs1333049, a representative SNP from the 9p21.3 locus,
with global gene expression in several key cardiovascular tissues,
including heart tissue from donors with no previously diagnosed
heart disease (predominant cause of death, cerebral vascular
accident) and carotid plaque tissues from carotid endarterectomy
patients. Our data suggest altered expression of multiple genes in
these tissues and we propose a common transcriptional mechanism
that might relate cardiovascular gene expression to the 9p21.3 risk
locus.
Results
Clinical Characteristics and Genotype Frequencies in
Heart Donors and Patients
The baseline characteristics of heart donors, heart valve patients
and carotid endarterectomy patients are listed in Table 1. For all
cohorts, the genotype frequencies were in Hardy-Weinberg
equilibrium (donors p=0.762, heart valve patients p=0.701,
carotid endarterectomy patients p=1.00) and were in concor-
dance with other European populations [6]. For heart donors,
associations between baseline characteristics and 9p21.3 genotype
are reported in Table 2.
Gene Expression Profile Associated with 9p21.3 Risk
Allele in Myocardium
To investigate associations between 9p21.3 genotype and gene
expression with minimal confounding from the influence of
advanced coronary artery disease, genome-wide analysis of
Affymetrix Human Gene 1.0 ST expression profiles was
performed in cardiac tissue from heart donors. Despite having
Table 1. Baseline characteristics of heart donors, heart valve patients and carotid endarterectomy patients.
Variable
Heart Donors
(n=108)
Heart Valve Patients
(n=104)
Carotid Endarterectomy
Patients (n=106)
Age* (years) 48613 62610 7069
Gender Male (%) 55 (51) 78 (75) 85 (80)
Female (%) 52 (48) 26 (25) 21 (20)
Ethnicity European (%) 104 (96) 104 (100) 106 (100)
African-American (%) 4 (4) 0 (0) 0 (0)
LVEF* (%) 52615% – –
Cause of Death Cerebral vascular accident (%) 78 (72) – –
Gunshot wound (%) 10 (9) – –
Motor vehicle accident (%) 9 (8) – –
Head trauma (%) 7 (7) – –
Other (%) 4 (4) – –
rs1333049 GG (%) 32 (30) 38 (37) 34 (32)
GC (%) 55 (51) 48 (46) 52 (49)
CC (%) 21 (19) 18 (17) 20 (19)
*mean6standard deviation.
doi:10.1371/journal.pone.0039574.t001
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spectrum of subclinical atherosclerosis, consistent with their mean
age of 48 years (Table 1). This analysis identified 59 gene
transcripts that were putatively differentially expressed in associ-
ation with the rs1333049 high-risk C allele (fold-change .1.1 per
copy) at the chosen level of significance (p,0.05, not corrected for
multiple comparisons). Of these, 46 transcripts remained signifi-
cantly associated with 9p21.3 genotype after adjustment for age,
gender, ethnicity and cause of death. The majority of these genes
(70%) were down-regulated in association with the risk allele, and
showed a modest fold-change in expression (median fold change
=1.12 per copy of the risk allele, range 1.10–1.33). Analysis of the
chromosomal location of the differentially expressed genes
revealed an even distribution throughout the genome with no
chromosome or cytoband significantly over-represented (Figure
S1).
The 20 most differentially expressed genes in heart donors are
shown in Figure 1 (p,0.05 adjusted for age, gender, ethnicity and
cause of death; additional information provided in Table S1). The
gene encoding the extracellular matrix protein periostin, POSTN,
was the most differentially expressed gene associated with
rs1333049 genotype (down-regulated 1.33-fold per copy of the
risk allele, p=0.002). This was confirmed by RT-qPCR in the
same samples, which showed that expression of POSTN was down-
regulated 1.84-fold per copy of the risk allele (95% CI 1.10–3.06,
p=0.020, Figure 2) and that 5% of the variance in POSTN levels
could be attributed to 9p21.3 genotype. Associations between
9p21.3 genotype and the expression of three other transcripts,
CCDC80, VCAM1 and GAP43, were also validated by RT-qPCR,
although statistical significance was only replicated for CCDC80
and VCAM1 (p=0.024 for both, Figure 2). While no associations
between the risk allele and expression of genes in close proximity
to the risk locus, including ANRIL, CDKN2A, CDKN2B and MTAP,
were detected by array, RT-qPCR analysis showed lower
expression of CDKN2B in individuals carrying the risk allele
(down-regulated 1.35-fold per copy of the risk allele, p=0.046,
Figure 2). RT-qPCR corroborated array data for CDKN2A and
ANRIL, which showed no significant difference between genotypes
(CDKN2A p=0.585; ANRIL p=0.541, Figure 2). Overall, expres-
sion levels of CDKN2B and CDKN2A, and CDKN2A and ANRIL
were positively correlated (Pearson correlation co-efficient
CDKN2B/CDKN2A=0.367, p=0.001; CDKN2A/ANRIL=0.252,
p=0.045). Expression of ANRIL and POSTN were also strongly
positively correlated (Pearson correlation co-efficient 0.658,
p=4.59610
212).
Using a false discovery rate (FDR) of 0.001, analysis of Gene
Ontology biological process (GO_biological process) terms asso-
ciated with the differentially expressed transcripts identified
significant enrichment for genes involved in response to wounding
(p-value from gene set enrichment analysis (GSEA): 2.65610
210),
cell migration (p-value from GSEA: 4.89610
29) and the
inflammatory response (p-value from GSEA: 1.97610
27), all
processes that contribute to the development and progression of
atherosclerosis. Consistent with these findings, analysis of propri-
etary GeneGo ontology terms (MetaCore database) revealed that
the differentially expressed transcripts were enriched for gene
biomarkers (genes previously reported to have altered expression
in disease) of inflammation (p-value from GSEA: 7.28610
29) and
myocardial infarction (p-value from GSEA: 1.53610
29), despite
originating from cardiac tissue with no diagnosed heart disease
(FDR=0.001). The subset of genes associated with each of these
GO_biological process and GeneGo ontology terms (25 genes in
total) were predominantly down-regulated in association with the
high-risk 9p21.3 allele (88%). Network analysis showed that these
genes mapped to a set of receptors through direct interactions and
formed part of a network of pathways that regulate a group of
transcription factors, including NF-kB (p-value from network
analysis: 1.25610
265, Figure S2).
To investigate whether the differentially expressed genes may be
co-regulated, the transcriptional control of the differentially
expressed genes was analysed. This showed that the gene set was
most strongly enriched by genes known to be regulated by the
transcription factor Sp1 (18 out of 46 genes, p-value from network
analysis: 4.83610
261). Of the 10 most down-regulated genes,
further analysis of the promoter regions revealed that specific
combinations of transcription factor binding sites were over-
represented among 7 of these genes: CCDC80, VCAM1, GAP43,
EGR1, TNFAIP6 CILP, BDNF (Figure 1). Consistent with the
Table 2. Baseline characteristics of heart donors by 9p21.3 (rs1333049) genotype and allele frequency.
Variable rs1333049 genotype allele
p-value
(additive model)
GG GC CC G C
Age* (years) 45.0613.9 49.4612.3 48.2611.2 – – 0.280
Gender Male (%) 18 (33) 27 (49) 10 (18) 0.57 0.43 0.519
Female (%) 14 (27) 27 (52) 11 (21) 0.53 0.47
Ethnicity European 29 (28) 52 (51) 21 (21) 0.54 0.46 0.237
A-A 2 (50) 2 (50) 0 (0) 0.75 0.25
LVEF* (%) 45616 57614 49614 – – 0.329
Cause of Death CVA (%) 19 (24) 42 (54) 17 (22) 0.51 0.49 0.230
GW (%) 3 (30) 6 (60) 1 (10) 0.60 0.40
MVA (%) 4 (44) 4 (44) 1 (11) 0.67 0.33
HT (%) 3 (43) 2 (28) 2 (28) 0.57 0.43
Other (%) 3 (75) 1 (25) 0 (0) 0.88 0.12
*mean6standard deviation.
A-A=African-American; CVA= cerebral vascular accident; GW=gunshot wound; HT=head trauma; LVEF=left ventricular ejection fraction; MVA= motor vehicle
accident.
doi:10.1371/journal.pone.0039574.t002
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GeneGo ontology terms above, these binding site signatures
comprised a NF-kB binding site in close proximity (,200 bases) to
an HMGB1 site (p-value from one-sided Fisher exact test:
1.14610
25) and a RelA (NF-kB subunit) binding site in close
proximity to a TATA binding protein site (6 genes, CILP not
included; p-value from one-sided Fisher exact test: 2.11610
27).
Transcription factor binding sites were located in evolutionarily
conserved regions of DNA that share more than 70% identity with
the mouse genome. No combinations of transcription factor
binding sites were identified among the promoter regions of the 10
most up-regulated genes in heart donors.
Combined Analysis of Gene Expression Profiles
Associated with the 9p21.3 Risk Allele Across Myocardial
and Vascular Tissues
To identify common pathways associated with the 9p21.3 risk
allele irrespective of differences in tissue type or disease state, an
analysis of the genes most significantly differentially expressed in
either myocardial, carotid plaque, aorta or mammary artery
tissues was performed. An expression fold-change threshold of
.1.10 per copy of the risk allele at a more conservative level of
significance of p,0.01 (not corrected for multiple comparisons)
was used for this analysis to reduce the potential confounding
influence of the presence of coronary artery disease in patient
samples and to obtain a feasible number of genes for canonical
pathway modeling (computationally intensive). This analysis of
expression profiles identified 59 gene transcripts in carotid plaque
(56% down-regulated), 20 transcripts in aorta (media/intima, 60%
down-regulated), 65 transcripts in mammary artery (media/
intima, 60% down-regulated) and 11 transcripts in donor heart
(73% down-regulated) tissues that were putatively differentially
expressed in association with the high-risk rs1333049 C allele (154
unique transcripts in total, 60% down-regulated, Table S2). No
transcripts were consistently altered in all tissues, although
ubiquitin specific peptidase 15 (USP15), a gene shown to induce
cardiac hypertrophy in mice [43], showed an equivalent increase
in expression in aorta and mammary artery tissues (aorta +1.16-
fold per copy of the risk allele, p=0.008; mammary artery +1.15-
fold, p=0.003). No significant associations were detected between
the risk allele and overall expression of genes in close proximity to
the risk locus (CDKN2A, CDKN2B, ANRIL, MTAP) in any of the
tissues (an expanded analysis of transcripts spanning a .10 Mb
region around the risk locus, from DMRTA1 to IFNB1, in heart
donors is provided in Table S3).
Canonical pathway modelling of the genes most significantly
altered in association with the 9p21.3 risk locus in myocardial and
vascular tissues combined, identified a highly significant associa-
tion with the cell cycle G1 phase progression pathway (p-value
from canonical pathway modelling: 1.08610
2258, Figure 3), in
which proteins encoded by CDKN2A and CDKN2B (p16 and p15,
respectively) play an important regulatory role. Of the 116 out of
154 differentially expressed genes associated with this pathway,
58% were down-regulated in association with the 9p21.3 risk allele
(Figure S3, Table S2). This analysis indicated that the differentially
expressed genes were most likely to be transcriptionally regulated
by this pathway, via transcription factors including E2F1, E2F4
and Sp1 (Figure 3). There were no combinations of transcription
factor binding sites in common among the 10 most up- or down-
regulated genes from each tissue. However, further analysis of the
transcriptional regulation of the combined set of differentially
expressed genes confirmed that they were most enriched for genes
regulated by Sp1 (33 genes, p-value from network analysis:
6.70610
285).
Discussion
Using genome-wide expression profiling, we have identified
genes whose expression patterns may be associated with the
9p21.3 CAD risk allele in donor myocardial tissue and in vascular
tissues from CAD patients. Within heart, shared combinations of
transcription factor binding sites among genes with putatively
altered expression suggested co-regulation of these genes by a
shared mechanism. Canonical pathway modeling of the most
differentially expressed genes across all tissues identified the cell
Figure 1. Twenty top-ranked genes altered in association with the 9p21.3 risk allele in donor hearts (n=108). Analysis was performed
using a fold-change threshold of .1.1 per copy of the risk allele and p,0.05 (adjusted for age, gender, ethnicity and cause of death; not corrected for
multiple comparisons). Each bar represents an individual gene, as indicated by the gene symbol. Genes are ranked in order of fold-change from
greatest to smallest (left to right). Analysis of the top 10 most down-regulated genes (indicated by line below graph) identified a shared combination
transcription factor binding sites within the promoter regions of 7 of these genes (genes indicated by asterisks).
doi:10.1371/journal.pone.0039574.g001
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regulating their expression. This pathway facilitates the activation
of genes required for cell cycle progression and cell proliferation
[44] and is controlled by proteins encoded by CDKN2A and
CDKN2B, two genes located adjacent to the 9p21.3 risk locus.
Hence, we propose that risk variants at 9p21.3 increase the
activation of this pathway in cardiovascular tissues, leading to a
proliferative phenotype that promotes cardiac hypertrophy and
vascular remodeling, and contributes to increased susceptibility to
atherosclerosis.
We report significantly lower expression levels of CDKN2B, but
not CDKN2A or ANRIL, in heart donors carrying the 9p21.3 risk
allele. Recent studies suggest that genetic variation within the
9p21.3 region may alter the expression of CDKN2B, CDKN2A,
ANRIL (the large non-coding RNA that spans the CAD risk locus),
and/or other genes on chromosome 9 located up to 1 Mb from
the risk locus [35,36,37,38,39,40]. Consistent with these findings,
Figure 2. Comparison of microarray data with real-time PCR for selected genes in donor hearts (n=108). Periostin, CCDC80 (coiled-coil
domain containing 80) and VCAM1 (vascular cell adhesion molecule 1), the most differentially expressed genes altered in association with the 9p21.3
risk allele in heart donors, gave an equivalent, statistically significant decrease in expression by microarray and RT-qPCR methods. In contrast to array
data, RT-qPCR for CDKN2B, a gene in close proximity to the 9p21.3 risk locus, also showed a significant decrease in expression. No significant
association between the 9p21.3 risk allele and expression levels of ANRIL or CDKN2A was detected in these individuals, by either method. The 9p21.3
(rs1333049) low-risk GG genotype is depicted in green; GC heterozygotes (intermediate risk) are shown in orange; the high-risk CC genotype is shown
in red. Statistical analysis was performed assuming an additive genetic model and all p-values have been adjusted for age, gender, ethnicity and
cause of death.
doi:10.1371/journal.pone.0039574.g002
Figure 3. Canonical pathway modeling of the most significantly differentially expressed genes in donor heart (n=108), carotid
plaque (n=106), aorta (n=104) and mammary artery (n=88) tissues. (A) A schematic depicting part of the cell cycle G1 phase progression
pathway, indicating the regulatory role of p16
INK4 and p15, which are encoded by two genes located adjacent to the 9p21.3 risk locus (CDKN2A and
CDKN2B). The majority of the most significantly differentially expressed genes (fold-change .1.1 per copy of the risk allele, p,0.01 not corrected for
multiple comparisons,) associated with the 9p21.3 risk allele in myocardial and vascular tissues were predicted to be transcriptionally regulated by
this pathway, predominantly by the transcription factors E2F1, E2F4 and Sp1 (116 out of 154 genes, see Table S2 for the list of genes associated with
this pathway and Figure S2 for gene network analysis). More than half of these genes (58%) were down-regulated in association with the 9p21.3 risk
allele, which would be concordant with lower levels of ANRIL expression. Green arrows indicate positive regulation; red arrows indicate negative
regulation. (B) Venn diagram indicating the proportion of differentially expressed genes predicted to be regulated by E2F1, E2F4 and Sp1. The genes
predicted to be regulated by each of these transcription factors is indicated by the symbols *, 1 and " respectively, in Table S2.
doi:10.1371/journal.pone.0039574.g003
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been reported in association with the 9p21.3 risk allele in aortic
smooth muscle cells [45]. These effects may be mediated by
disruption of enhancer elements within the risk locus [35] and/or
by altering expression of ANRIL splice variants or overall transcript
levels [35,36,37,38,39,40]. These findings are concordant with the
phenotype of the Chr4
D70kb/D70kb knock-out mouse, in which
targeted deletion of the orthologous 9p21.3 risk interval on mouse
chromosome 4 resulted in severely reduced expression of nearby
genes, including CDKN2A and CDKN2B, and increased prolifer-
ation of vascular cells [46].
Our study analyzed genes from myocardial and vascular tissues
that were putatively altered in association with the 9p21.3 risk
allele to identify common pathways downstream of these modest
effects that are relevant to CAD. We found that 75% of the most
differentially expressed genes across all tissues, regardless of disease
state, were predicted to be regulated by the pathway that controls
the cell cycle transition from G1 to S phase (Figure 3). This
pathway activates the E2F family of transcription factors,
including E2F1 [47]. In addition to activating genes involved in
cell proliferation, E2F1 has been shown to function as an
inhibitory regulator for the inflammatory mediator NF-kB and
down regulate cytokine-induced expression of adhesion molecules,
including VCAM1 [48]. Our data in heart tissue suggests down-
regulation of multiple genes associated with inflammation and
adhesion processes, including VCAM1. Furthermore, the shared
transcription factor binding site signatures identified among
conserved promoter regions of 7 of the top 10 most down-
regulated genes, included either a Nf-kB or RelA (a subunit of NF-
kB) binding site. Together, these results suggest that the cell cycle
G1 phase progression pathway is activated in individuals with the
9p21.3 risk allele. This may promote a proliferative phenotype
that leads to adverse cardiac hypertrophy and vascular remodel-
ing, and an increased susceptibility to CAD. This is consistent with
the findings of Jarinova et al [37], who reported altered expression
of genes involved in cell proliferation in association with the
9p21.3 risk allele, in whole blood from healthy subjects and stable
CAD patients. Activation of this pathway may be one of the
mechanisms by which CAD risk variants may increase CAD risk.
The mechanism underlying increased activation of the cell cycle
G1 phase progression pathway in individuals with the 9p21.3 risk
allele may center on two genes located adjacent to the risk locus,
CDKN2A and CDKN2B. These genes block this pathway by
inhibiting the cyclin-dependent kinases (CDK) 4 and 6. Previous
studies suggest that total expression levels of CDKN2A, CDKN2B
and ANRIL are positively correlated in blood and tissues
[34,38,40], with expression of ANRIL and one or both of CDKN2A
and CDKN2B reported to be down-regulated in association with
the risk allele [34,37,38], consistent with our study. In support of
this, Harismendy et al [35] found that CAD risk SNPs altered the
sequence of an enhancer element within the 9p21.3 risk locus and
disrupted long-range physical interactions between the enhancer
and the CDKN2A/B locus. To add another layer of complexity,
expression of ANRIL splice variants may also be altered in
individuals with the risk allele [36,37], although splicing varies by
tissue type [40]. In whole blood, Jarinova et al. [37] showed
increased expression of short splice variants and decreased
expression of a long splice variant of ANRIL association with the
risk allele. Expression of the long ANRIL splice variant was
correlated with expression of CDKN2B, suggesting that the shift
from long to short splice variants may influence the expression of
nearby genes. Although ANRIL has been shown to repress
expression of CDKN2A and CDKN2B through recruitment and
retention of polycomb repressive protein complexes at the 9p21.3
locus [41,42], it is unknown whether short or other alternatively
spliced ANRIL transcripts may increase the efficiency of this
epigenetic mechanism. Further research is needed to determine
whether protein levels of p16 (CDKN2A) and/or p15 (CDKN2B) are
down-regulated in association with the 9p21.3 risk allele in tissues
relevant to the development of CAD. This would be predicted to
increase activation of the cell cycle G1 phase progression pathway
and promote a proliferative phenotype.
It is unknown whether the modest putative changes in gene
expression observed in the current study would be sufficient to
promote the development of CAD in individuals with the 9p21.3
risk allele. Of particular relevance is the observation that deletion
of the equivalent 9p21.3 risk region in mice did not cause CAD,
despite a marked reduction in CDKN2A and CDKN2B expression
and a proliferative phenotype [46]. This suggests that other factors
may be required for the development of CAD and that activation
of the cell cycle G1 phase progression pathway may represent just
one aspect of the mechanism underlying the association between
the 9p21.3 risk allele and increased CAD risk. Moreover, none of
the genes identified as having altered expression in association
with the 9p21.3 risk allele remained significant after correction for
multiple comparisons and these findings need to be validated in an
independent sample set. It should also be noted that the majority
of heart donors were on life-support as a result of head trauma or
cerebral vascular accident and thus the myocardial gene expres-
sion profile may have been affected by the traumatic injuries, acute
drug treatments and underlying sub-clinical cardiac disease prior
to the donation of tissue. Similarly, the gene expression profiles of
vascular tissues were likely to have been affected by chronic drug
treatment.
In summary, our data suggest that the 9p21.3 CAD risk locus
may be associated with an altered pattern of gene expression in
myocardial tissue from donors with no diagnosed heart disease and
in vascular tissues from heart patients. These expression profiles,
while tissue-specific, may be regulated through the cell cycle G1
phase progression pathway, which is inhibited by proteins encoded
by CDKN2A and CDKN2B, two genes located adjacent to the risk
locus. We speculate that the CAD risk variants decrease expression
of CDKN2A and CDKN2B, which leads to activation of CDK4,
CDK6, and downstream transcription factors, including E2F1,
E2F4 and Sp1, and to altered expression of their target genes. Our
data suggests that this network of genes may be altered in
association with 9p21.3 risk SNPs in cardiovascular tissues, both
before and after the onset of overt disease. These findings may
help elucidate one of the mechanisms by which the 9p21.3 locus
contributes to increased CAD risk.
Methods
Human Samples
Donor Heart Tissue. Heart tissue from the left ventricular
free wall of organ donors was collected by the Cleveland Clinic
Kaufman Center for Heart Failure human heart tissue bank
(n=108) between August 1993 - May 2005. Heart specimens were
rapidly frozen in liquid nitrogen at the time of harvest and stored
at 280uC until use. The decision that the heart could not be used
for transplantation was made by members of the clinical organ
procurement team. Reasons for rejection included histocompat-
ibility mismatch, structural damage to the heart, cardiac disease or
other elements of the medical history that made the donor
undesirable. The research team was not contacted until donation
for transplant had been ruled out and the family provided
informed written consent to use the heart for research. The study
was approved by the Cleveland Clinic Institutional Review Board
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Aorta, Mammary Artery and Carotid Plaque
Tissue. Tissue from the media/intima layers of aorta (n=104)
and mammary artery (n=88) were collected from Swedish
patients undergoing aortic valve surgery or surgery for aortic
aneurysm and carotid plaque tissue was collected from 106
Swedish patients undergoing carotid endarterectomy as previously
described [40]. All patients provided informed written consent.
The study was approved by the Karolinkska University ethics
committee (01–199, 02–146, 02–147, 2006/784–31/1, 2005/
880–31/3) and all procedures were in accordance with institu-
tional guidelines.
Sample Preparation and Genotyping
Donor Heart Tissue. Total RNA and genomic DNA was
simultaneously extracted from frozen tissue after automated
grinding (Retsch Mixer Mill MM301, Haan, Germany) in
TRIzolH (Invitrogen, Carlsbad, CA) and chloroform [49]. RNA
was purified using RNeasy Midi columns (Qiagen, Valencia, CA)
according to manufacturer’s instructions and tested for quantity
and quality (by visual assessment of gel plots) with an Experion
(Bio-Rad Laboratories, Hercules, CA). RNA samples were
digested with DNase I (Invitrogen). First strand cDNA synthesis
was performed from 2 mg of total RNA with Superscript III
(Invitrogen), followed by RNase H digestion (Invitrogen) as
previously described [50]. Genomic DNA was extracted from
the remaining organic and interphase layers of the TRIzolH
extract (see protocol at http://genome-www.stanford.edu/DFSP/
materials.shtml). Individuals were genotyped in duplicate for
rs1333049 with Taqman SNP assay C_1754666_10 (Applied
Biosystems, Foster City, CA) on a Rotor-Gene 3000 and analyzed
with Rotor-Gene version 6.1 software (Corbett Research, Sydney,
Australia). Reactions were optimized for 10 mL volumes with 0.56
the recommended probe concentration. Genotypes were validated
for a subset of randomly selected samples by re-genotyping (n=66)
or sequencing (n=7, see Methods S1 and Table S4 for primer
sequences). Both methods gave 100% concordance with original
genotypes.
Aorta, Mammary Artery and Carotid Plaque
Tissues. Total RNA was isolated from tissues and genomic
DNA was isolated from peripheral blood leukocytes as previously
described [40]. Genotyping for rs1333049 was performed for aorta
and mammary artery samples with custom printed Cardiometabo
chips (Illumina, San Diego, CA) on an iScan instrument (Illumina).
Genotypes for the carotid plaque samples were imputed from
Human 610W-Quad Bead array (Illumina) data [51].
Microarrays
Donor Heart Tissue. Individual myocardial gene expression
profiles were generated for all samples with Human Gene 1.0 ST
arrays (Affymetrix, Santa Clara, CA) according to manufacturer’s
instructions (GEO accession: GSE22253). These arrays use 25-
mer oligonucleotides to measure mRNA transcript abundance and
consist of 844,550 probes representing approximately 27,900
transcripts [52]. Probe intensities were estimated using linear
models fitted to Robust Multi-Array (RMA)-background corrected
and quantile normalized data with R software (http://www.R-
project.org) and the Aroma.affymetrix (http://groups.google.
com/group/aroma-affymetrix) and Bioconductor Limma packag-
es [53,54]. Transcripts were annotated using the file HuGene-1_0-
st-v1.na25.hg18.transcript.csv created on 20 March 2008 available
from http://www.affymetrix.com/support/technical/byproduct.
affx? product=hugene-1_0-st-v1. Associations between
rs1333049 genotype and myocardial gene expression were tested
with R software and the Bioconductor Limma package [53,54]
using an additive genetic model (see Figure S4 for QQ plot). None
of the associations remained significant after correcting for
multiple comparisons using the method of Benjamini and
Hochberg [55], and unadjusted p-values have been reported.
Genes altered .1.1-fold per copy of the risk allele at an unadjusted
p-value ,0.05 that remained significant after adjusting for age,
gender, ethnicity and cause of death (dichotomized as ‘cerebral
vascular accident’ or ‘other’) were considered to be of potential
biological significance. The conservative fold-change threshold
(.1.1-fold per copy of the risk allele) was applied to limit
bioinformatic analyses to those transcripts most likely to have a
functional effect, however this may have resulted in some false-
negative associations.
Aorta, Mammary Artery and Carotid Plaque
Tissues. Individual gene expression profiles were generated
for aorta and mammary artery samples with Human Exon 1.0 ST
arrays (Affymetrix) and for carotid plaque samples with HG-U133
plus 2.0 arrays (Affymetrix, GEO accession: GSE21545) as
previously described [51]. Gene array analysis of aorta, mammary
artery and carotid plaque samples was performed using a additive
genetic model, as previously described [40] (see Figure S4 for QQ
plots).
Real-Time PCR in Donor Heart Tissue
To validate array data in donor hearts, real-time PCR (RT-
qPCR) was performed using Taqman gene expression assays with
inventoried probes (Applied Biosystems) for POSTN (assay
Hs00170815_m1), CCDC80 (Hs00277341_m1), VCAM1
(Hs01003372_m1) and GAP43 (Hs00967138), the most differen-
tially expressed genes putatively associated with rs1333049
genotype, and for ANRIL (Hs01390879_m1), CDKN2A
(Hs00923894_m1) and CDKN2B (Hs00793225_m1), genes adja-
cent to the 9p21.3 risk locus. Reactions (20 mLo r1 0mL) were
performed in triplicate or duplicate on a 7500 Fast Real-Time
PCR System (Applied Biosystems) or a Lightcycler 480 Real-Time
PCR system (Roche Diagnostics, Indianapolis, IN) according to
manufacturer’s instructions. Quantification was performed with
7500 software version 2.0 (Applied Biosystems) or Lightcycler 480
software release 1.5.0 (Roche). Expression levels were converted to
relative quantities and normalized to signal recognition particle 14
(SRP14), tumour protein translationally controlled 1 (TPT1) and
eukaryotic elongation factor 1A1 (EEF1A1), as previously
described [56]. RT-qPCR gene expression data displayed
consistently skewed distributions and were log-transformed prior
to analysis. Associations between gene expression and 9p21.3
genotype were tested with linear regression adjusting for potential
confounding factors (age, gender, ethnicity and cause of death
dichotomized as ‘cerebral vascular accident’ or ‘other’) using SPSS
Statistics software, version 19 (IBM). Data on post-mortem interval
(the time between death and tissue collection) was unavailable and
gene expression analyses were not adjusted for this factor. Relative
expression levels of POSTN, CCDC80, VCAM1, GAP43, CDKN2B,
CDKN2A and ANRIL were calculated from RT-qPCR and
microarray data using geometric means and standard errors. No
RT-qPCR analyses were performed in human vessel samples.
Bioinformatic Analysis
Chromosomal Distribution of Differentially Expressed
Genes. The chromosomal distribution of differentially expressed
genes was analyzed using the Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID) version 6.7 [57,58]
functional annotation tool and visualized using the R/Bioconduc-
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packages/2.3/bioc/html/geneplotter.html) based on annotation
from hugene10st.db (http://www.bioconductor.org/packages/2.
3/data/annotation/html/hugene10st.db.html) originally sourced
from Entrez Gene on April 2, 2008.
Gene Set Enrichment Analysis (GSEA). The biological
functions of the differentially expressed genes in heart donors was
analyzed with Gene Ontology – biological process terms
(GO_biological process, www.geneontology.org) and proprietary
GeneGo ontology terms using the MetaCore database (GeneGo
Inc, St Joseph, MI) functional enrichment by ontology tool. The
MetaCore database (GeneGo Inc) includes a manually curated
database of human protein-protein, protein-DNA and protein-
compound interactions, metabolic and signaling pathways.
GeneGo ontologies are represented by canonical pathway maps,
cellular process networks, disease biomarker networks, drug target
networks, toxicity networks and metabolic networks. The
functional enrichment by ontology tool ranks the relevance of
matches between the set of differentially expressed genes and
GO_biological process and GeneGo ontology terms on the
probability of the match occurring by chance, given the size of
the database (p-value from GSEA). For all gene set enrichment
analyses, the false discovery rate (FDR) was set at 0.001 to limit the
number of false positive results to 0.1%.
Network Analysis. The relationship between the subset of
differentially expressed genes in heart donors associated with
GO_biological process and GeneGo ontology terms was analyzed
with the MetaCore database (GeneGo Inc) analyze network
(receptors) algorithm, using the default settings. Briefly, this
algorithm generates a list of receptors and transcription factors
closely associated with the differentially expressed genes (initial
gene set) based on interactions contained within the MetaCore
database, then builds a network for each receptor consisting of all
the shortest paths (ie the smallest possible number of direct
interactions) from the receptor to the nearest transcription factors.
The probability that the intersection between the initial gene set
and the genes/proteins in the network occurs by chance, given the
size of the initial gene set, the network and the interaction database
(p-value from network analysis), follows a hypergeometric distri-
bution and was used to rank the relevance of the networks
generated.
The association between individual transcription factors and
differentially expressed genes in heart and vascular tissues was
analyzed with the MetaCore database (GeneGo Inc) transcription
regulation algorithm. This algorithm identifies the shortest path of
direct interactions from the differentially expressed genes (the
initial gene set) to the nearest transcription factors based on
interactions in the MetaCore database, then builds a network for
each transcription factor identified. The transcription factor
networks were ranked on their statistical significance as described
for the algorithm above.
Enrichment Analysis for Combinations of Transcription
Factor Binding Sites (TFBS). Promoter regions (21500 bases
to +200 bases from the transcription start site) of the top 10 most
up- or down-regulated genes from each tissue were extracted and
analyzed computationally for common transcription factor bind-
ing sites using oPOSSUM [59]. oPOSSUM determines the over-
representation of transcription factor binding sites (TFBS) within a
set of co-expressed genes compared with a pre-compiled
background set. The background set comprises computationally
predicted TFBS within evolutionarily conserved regions +/
210,000 bases of the predicted transcription factor start site in
genes that are orthologous in human and mouse. To limit the
number of false positive binding sites identified, the analysis was
restricted to regions within the promoter that had .70% sequence
identity between human and mouse and the transcription factor
inter-binding distance was limited to a maximum of 200 base
pairs. A one-tailed Fisher exact test was used to determine
probability of a non-random association between the initial set of
co-expressed genes and the combination of transcription factor
binding sites identified.
Canonical Pathway Modelling. To identify pathways asso-
ciated with the 9p21.3 risk allele across all tissues, canonical
pathway modelling of the differentially expressed genes from all
tissues combined was performed with the MetaCore database
(GeneGo Inc) canonical pathway modelling algorithm, using the
default settings. Genes altered .1.1-fold per copy of the risk allele
at a p-value ,0.01 (not corrected for multiple comparisons) from
each tissue were considered to be of potential biological relevance
and comprised the initial gene set for this analysis. A more
stringent p-value threshold was selected to reduce the potential
confounding influence of the presence of coronary artery disease in
the patient samples and to obtain a feasible number of genes for
canonical pathway modeling, which is computationally intensive.
Briefly, this algorithm identifies all canonical pathways in the
database that include genes in the initial gene set, then builds
networks consisting of all genes/proteins and interactions from all
such pathways. The networks were ranked on the probability that
the intersection between the initial gene set and the genes/proteins
in the network occured by chance, which is calculated using the
hypergeometric probability distribution and takes into account the
size of the initial gene set, the network and the number of genes/
proteins associated with canonical pathways in the database (p-
value from canonical pathway modelling).
Supporting Information
Figure S1 Chromosomal location of 46 transcripts
identified as altered in association with the 9p21.3 risk
allele (rs1333049) in the myocardium of donors. Green
bars indicate the location of transcripts that were up-regulated in
association with the 9p21.3 risk allele; red bars indicate the
location of transcripts that were down-regulated in association
with the 9p21.3 risk allele (fold-change .1.1 per copy of the risk
allele, p,0.05 adjusted for age, gender, ethnicity and cause of
death; not corrected for multiple comparisons). The differentially
expressed transcripts were not significantly clustered within
individual chromosomes or within particular chromosomal
regions.
(TIFF)
Figure S2 Network analysis of 25 differentially ex-
pressed genes associated with gene ontology and
MetaCore database biological process and biomarker
terms in heart donors (n=108). These genes mapped to a
single network that integrated several intracellular signalling
pathways, potentially leading to regulation of multiple transcrip-
tion factors. Most of the genes (70%) were down-regulated in
association with the high-risk 9p21.3 allele (fold-change .1.1 per
copy of the risk allele, p,0.05 adjusted for age, gender, ethnicity
and cause of death; not corrected for multiple comparisons). The
differentially expressed genes are indicated by red (up-regulated)
or blue (down-regulated) circles adjacent to each gene, with the
intensity of the colour representative of the magnitude of the fold-
change in expression. Thick green lines indicate relationships
between proteins that form part of canonical pathways.
(TIFF)
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significantly differentially expressed genes in donor
heart (n=108), carotid plaque (n=106), aorta (n=104)
and mammary artery (n=88) tissues. The majority of the
most significantly differentially expressed genes (116 out of 154
genes, fold-change .1.1 per copy of the risk allele, p,0.01 not
corrected for multiple comparisons) associated with the 9p21.3 risk
allele in myocardial and vascular tissues were predicted to be
transcriptionally regulated by this gene network, which forms part
of the cell cycle G1 phase progression pathway. Of these genes,
most were predicted to be regulated by the transcription factors
E2F1, E2F4 and Sp1 (see Table S2 for the complete list of genes
associated with this pathway, with those genes predicted to be
regulated by E2F1, E2F4 and Sp1 indicated by the symbols *, 1
and " respectively). The differentially expressed genes are
indicated by red (up-regulated) or blue (down-regulated) circles
adjacent to each gene, with the intensity of the colour
representative of the magnitude of the fold-change in expression.
Thick green lines indicate relationships between proteins that form
part of canonical pathways.
(TIFF)
Figure S4 QQ Plots for assessing the effect of 9p21.3
genotype on global gene expression in donor heart
(n=108), carotid plaque (n=106), aorta (n=104) and
mammary artery (n=88) tissues. Each plot compares the
distribution of p-values for all associations (y-axis) against a
theoretical distribution of p-values assuming no effect (x-axis). For
donor heart and vascular tissues, the observed distribution of p-
values matched the theoretical null distribution or deviated below
the line y=x, suggesting that any associations between gene
expression and 9p21.3 genotype may have occurred by chance.
Consequently, none of the associations remained significant after
correction for multiple comparisons.
(TIFF)
Table S1 The 20 most differentially expressed genes
associated with the 9p21.3 risk allele in myocardium
from 108 heart donors (fold-change .1.1 per copy of the
risk allele, unadjusted p,0.05).
(DOCX)
Table S2 The most significantly differentially ex-
pressed genes associated with the 9p21.3 risk allele in
donor myocardium, and patient aorta, mammary artery
and carotid plaque tissues (fold-change .1.1 per copy of
the risk allele, unadjusted p,0.01).
(DOCX)
Table S3 Affymetrix microarray analysis of associa-
tions between 9p21.3 (rs1333049) genotype and tran-
scripts adjacent to the risk locus in heart donors.
(DOCX)
Table S4 PCR Primers for Sequencing rs1333049.
(DOCX)
Methods S1
(DOCX)
Acknowledgments
We gratefully acknowledge the donation of human myocardium, aorta,
mammary artery and carotid plaque for research purposes.
Author Contributions
Conceived and designed the experiments: VAC APP RWT CSM WHWT.
Performed the experiments: WES APP LM. Analyzed the data: JFP CMB
MAB APP. Wrote the paper: APP. Conceived the study: VAC APP RWT
CSM WHWT. Provided donor heart tissue for the study: CSM WES.
Prepared the heart donor tissue, RNA and DNA samples: WES APP.
Performed the array experiments: LM. Provided gene expression and
genotyping data for aorta, mammary artery and carotid plaque tissues: LF
AFC AG PE. Performed the genotyping and wrote the first draft of the
manuscript: APP. Performed the RT-qPCR analysis of the donor hearts:
APP NMW. Performed statistical and bioinformatic analysis: APP JFP
CMB MAB APP. Provided clinical input: WHWT RWT AMR.
Contributed to the interpretation of the data and revision of the
manuscript: APP LF JFP CMB LM NMW WES WHWT MAB RWT
AMR AFC AG PE CSM VAC. Obtained funding for the study: APP VAC
RWT AMR CSM AG PE.
References
1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and
regional burden of disease and risk factors, 2001: systematic analysis of
population health data. Lancet 367: 1747–1757.
2. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U (1994) Genetic
susceptibility to death from coronary heart disease in a study of twins.
N Engl J Med 330: 1041–1046.
3. (2007) Genome-wide association study of 14,000 cases of seven common diseases
and 3,000 shared controls. Nature 447: 661–678.
4. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, et al.
(2007) A common variant on chromosome 9p21 affects the risk of myocardial
infarction. Science 316: 1491–1493.
5. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al. (2007) A
common allele on chromosome 9 associated with coronary heart disease. Science
316: 1488–1491.
6. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. (2007)
Genomewide association analysis of coronary artery disease. N Engl J Med 357:
443–453.
7. Abdullah KG, Li L, Shen GQ, Hu Y, Yang Y, et al. (2008) Four SNPS on
chromosome 9p21 confer risk to premature, familial CAD and MI in an
American Caucasian population (GeneQuest). Ann Hum Genet 72: 654–657.
8. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, et al. (2008)
Susceptibility locus for clinical and subclinical coronary artery disease at
chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 17:
2320–2328.
9. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, et al. (2008)
Susceptibility to coronary artery disease and diabetes is encoded by distinct,
tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet
17: 806–814.
10. Hinohara K, Nakajima T, Takahashi M, Hohda S, Sasaoka T, et al. (2008)
Replication of the association between a chromosome 9p21 polymorphism and
coronary artery disease in Japanese and Korean populations. J Hum Genet 53:
357–359.
11. Larson MG, Atwood LD, Benjamin EJ, Cupples LA, D’Agostino RB, Sr., et al.
(2007) Framingham Heart Study 100 K project: genome-wide associations for
cardiovascular disease outcomes. BMC Med Genet 8 Suppl 1: S5.
12. Schunkert H, Gotz A, Braund P, McGinnis R, Tregouet DA, et al. (2008)
Repeated replication and a prospective meta-analysis of the association between
chromosome 9p21.3 and coronary artery disease. Circulation 117: 1675–1684.
13. Shen GQ, Li L, Rao S, Abdullah KG, Ban JM, et al. (2008) Four SNPs on
chromosome 9p21 in a South Korean population implicate a genetic locus that
confers high cross-race risk for development of coronary artery disease.
Arterioscler Thromb Vasc Biol 28: 360–365.
14. Shen GQ, Rao S, Martinelli N, Li L, Olivieri O, et al. (2008) Association
between four SNPs on chromosome 9p21 and myocardial infarction is replicated
in an Italian population. J Hum Genet 53: 144–150.
15. Talmud PJ, Cooper JA, Palmen J, Lovering R, Drenos F, et al. (2008)
Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk
of CHD in healthy middle-aged men. Clin Chem 54: 467–474.
16. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-
wide association study of type 2 diabetes in Finns detects multiple susceptibility
variants. Science 316: 1341–1345.
17. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007)
Replication of genome-wide association signals in UK samples reveals risk loci
for type 2 diabetes. Science 316: 1336–1341.
18. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir
V, et al. (2008) The same sequence variant on 9p21 associates with myocardial
9p21 and Gene Expression in Heart and Vessels
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39574infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet
40: 217–224.
19. Gschwendtner A, Bevan S, Cole JW, Plourde A, Matarin M, et al. (2009)
Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke.
Ann Neurol 65: 531–539.
20. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF (2008) Whole
genome analyses suggest ischemic stroke and heart disease share an association
with polymorphisms on chromosome 9p21. Stroke 39: 1586–1589.
21. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, et al. (2009)
Genome-wide association study identifies three loci associated with melanoma
risk. Nat Genet 41: 920–925.
22. Chen J, Li D, Wei C, Sen S, Killary AM, et al. (2007) Aurora-A and p16
polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in
Caucasians. Clin Cancer Res 13: 3100–3104.
23. Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, et al. (2005) A common
variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 42: 763–
765.
24. Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, et al. (2008)
Association of single-nucleotide polymorphisms in the cell cycle genes with
breast cancer in the British population. Carcinogenesis 29: 333–341.
25. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, et al. (2007)
Tagging single nucleotide polymorphisms in cell cycle control genes and
susceptibility to invasive epithelial ovarian cancer. Cancer Res 67: 3027–3035.
26. Healy J, Belanger H, Beaulieu P, Lariviere M, Labuda D, et al. (2007) Promoter
SNPs in G1/S checkpoint regulators and their impact on the susceptibility to
childhood leukemia. Blood 109: 683–692.
27. Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, et al. (2001) A single
nucleotide polymorphism in the 39untranslated region of the CDKN2A gene is
common in sporadic primary melanomas but mutations in the CDKN2B,
CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 95: 388–393.
28. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. (2009)
Genome-wide association study identifies five susceptibility loci for glioma. Nat
Genet 41: 899–904.
29. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, et al. (2009) Variants in
the CDKN2B and RTEL1 regions are associated with high-grade glioma
susceptibility. Nat Genet 41: 905–908.
30. Melzer D, Frayling TM, Murray A, Hurst AJ, Harries LW, et al. (2007) A
common variant of the p16(INK4a) genetic region is associated with physical
function in older people. Mech Ageing Dev 128: 370–377.
31. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, et al. (2011)
Large-scale association analysis identifies 13 new susceptibility loci for coronary
artery disease. Nat Genet 43: 333–338.
32. Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, et al. (2009)
Impact of adding a single allele in the 9p21 locus to traditional risk factors on
reclassification of coronary heart disease risk and implications for lipid-
modifying therapy in the Atherosclerosis Risk in Communities study. Circ
Cardiovasc Genet 2: 279–285.
33. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, et al. (2007)
Characterization of a germ-line deletion, including the entire INK4/ARF locus,
in a melanoma-neural system tumor family: identification of ANRIL, an
antisense noncoding RNA whose expression coclusters with ARF. Cancer Res
67: 3963–3969.
34. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B (2010)
Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes
Correlate with ANRIL Expression. PLoS Genet 6: e1000899.
35. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, et al. (2011) 9p21
DNA variants associated with coronary artery disease impair interferon-gamma
signalling response. Nature 470: 264–268.
36. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, et al. (2010) Expression of
linear and novel circular forms of an INK4/ARF-associated non-coding RNA
correlates with atherosclerosis risk. PLoS Genet 6: e1001233.
37. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, et al. (2009) Functional
analysis of the chromosome 9p21.3 coronary artery disease risk locus.
Arterioscler Thromb Vasc Biol 29: 1671–1677.
38. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, et al. (2009) INK4/ARF
transcript expression is associated with chromosome 9p21 variants linked to
atherosclerosis. PLoS One 4: e5027.
39. Holdt LM, Beutner F, Scholz M, Gielen S, Gabel G, et al. (2010) ANRIL
expression is associated with atherosclerosis risk at chromosome 9p21.
Arterioscler Thromb Vasc Biol 30: 620–627.
40. Folkersen L, Kyriakou T, Goel A, Peden J, Malarstig A, et al. (2009)
Relationship between CAD risk genotype in the chromosome 9p21 locus and
gene expression. Identification of eight new ANRIL splice variants. PLoS One 4:
e7677.
41. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, et al. (2010) Molecular
interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27
by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662–
674.
42. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, et al. (2008) Epigenetic
silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451: 202–
206.
43. Isumi Y, Hirata T, Saitoh H, Miyakawa T, Murakami K, et al. (2011)
Transgenic overexpression of USP15 in the heart induces cardiac remodeling in
mice. Biochem Biophys Res Commun 405: 216–221.
44. Dimova DK, Dyson NJ (2005) The E2F transcriptional network: old
acquaintances with new faces. Oncogene 24: 2810–2826.
45. Almontashiri N, Fan M, Chen H-H, Teng A, Chen B, et al. (2011) Abstract
15730: Serum Interferon Alpha 21 is a Biomarker of the 9p21.3 Risk Locus for
Coronary Artery Disease. American Heart Association Scientific Sessions 2011.
Orlando, FL: Circulation. A15730.
46. Visel A, Zhu Y, May D, Afzal V, Gong E, et al. (2010) Targeted deletion of the
9p21 non-coding coronary artery disease risk interval in mice. Nature 464: 409–
412.
47. Frolov MV, Dyson NJ (2004) Molecular mechanisms of E2F-dependent
activation and pRB-mediated repression. Journal of cell science 117: 2173–2181.
48. Chen M, Capps C, Willerson JT, Zoldhelyi P (2002) E2F-1 regulates nuclear
factor-kappaB activity and cell adhesion: potential antiinflammatory activity of
the transcription factor E2F-1. Circulation 106: 2707–2713.
49. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:
156–159.
50. Ellmers LJ, Scott NJ, Piuhola J, Maeda N, Smithies O, et al. (2007) Npr1-
regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol
Endocrinol 38: 245–257.
51. Folkersen L, van’t Hooft F, Chernogubova E, Agardh HE, Hansson GK, et al.
(2010) Association of genetic risk variants with expression of proximal genes
identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc
Genet 3: 365–373.
52. Robinson MD, Speed TP (2007) A comparison of Affymetrix gene expression
arrays. BMC Bioinformatics 8: 449.
53. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
54. Smyth G (2005) Limma: linear models for microarray data. In: Gentleman R,
Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and
Computational Biology Solutions using R and Bioconductor. New York:
Springer. 397–420.
55. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a
Practical and Powerful Approach to Multiple Testing. Journal of the Royal
Statistical Society Series B-Methodological 57: 289–300.
56. Pilbrow AP, Ellmers LJ, Black MA, Moravec CS, Sweet WE, et al. (2008)
Genomic selection of reference genes for real-time PCR in human myocardium.
BMC Med Genomics 1: 64.
57. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nature
protocols 4: 44–57.
58. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment
tools: paths toward the comprehensive functional analysis of large gene lists.
Nucleic acids research 37: 1–13.
59. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, et al. (2005)
oPOSSUM: identification of over-represented transcription factor binding sites
in co-expressed genes. Nucleic Acids Res 33: 3154–3164.
9p21 and Gene Expression in Heart and Vessels
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39574